Value-based agreements for acute hepatic porphyria therapy Givlaari launch

Alnylam Pharmaceuticals announced a new and enhanced framework for value-based agreements designed to provide access to the recently FDA-approved Givlaari for patients with acute hepatic porphyria, according to a press release.Alnylam is in active discussions with leading payers about such value-based agreements for Givlaari (givosiran) and Alnylam has reached an agreement in principle with Harvard Pilgrim.“Patients can sometimes experience lengthy delays waiting for access when a new medicine becomes available, as payers can be challenged to determine both which patients may bestRead More

Share on facebook
Share on twitter
Share on linkedin